Patents by Inventor Levi Blazer

Levi Blazer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132600
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20230118983
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: June 22, 2022
    Publication date: April 20, 2023
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Patent number: 8865750
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 21, 2014
    Assignees: The Regents of The University of Michigan, The University of Bath
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor
  • Publication number: 20120277273
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor